Xofluza

RSS

baloxavir marboxil

Authorised
This medicine is authorised for use in the European Union.

Overview

Xofluza is an antiviral medicine for treating and preventing flu in adults and children from 12 years of age.

As a treatment, Xofluza is only used for uncomplicated flu (flu without serious effects that may require hospital care).

Xofluza contains the active substance baloxavir marboxil.

This EPAR was last updated on 22/01/2021

Authorisation details

Product details
Name
Xofluza
Agency product number
EMEA/H/C/004974
Active substance
Baloxavir marboxil
International non-proprietary name (INN) or common name
baloxavir marboxil
Therapeutic area (MeSH)
Influenza, Human
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Roche Registration GmbH
Date of issue of marketing authorisation valid throughout the European Union
07/01/2021
Contact address

Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

Product information

07/01/2021 Xofluza - EMEA/H/C/004974 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Treatment of influenza
Xofluza is indicated for the treatment of uncomplicated influenza in patients aged 12 years and above.

Post exposure prophylaxis of influenza
Xofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 12 years and above. Xofluza should be used in accordance with official recommendations.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating